Type II FUS-CHOP mRNA expression was successfully detected in 20 of the 39 MRCLs cases (51.3%) positive for PGK mRNA expression, and no type I FUS-CHOP mRNA was detected, whereas 60 cases of control tumors were all negative for FUS-CHOP gene expression.